Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 65, Issue 7, Pages 5149-5183Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.1c01714
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81922064, 82073318, 81874290, 81903502]
- National Major Scientific and Technological Special Project for Significant New Drugs Development [2018ZX09201018-021]
- Sichuan Science and Technology Program [2019YFS0003]
- National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University [Z20201004]
Ask authors/readers for more resources
EGFR dual-target inhibitors play an important role in the treatment of EGFR-mutant non-small-cell lung cancer by reducing drug resistance risk and improving efficacy with fewer adverse effects.
Epidermal growth factor receptor (EGFR) is of great significance in mediating cell signaling transduction and tumorbehaviors. Currently, third-generation inhibitors of EGFR, especiallyosimertinib, are at the clinical frontier for the treatment of EGFR-mutant non-small-cell lung cancer (NSCLC). Regrettably, therapidly developing drug resistance caused by EGFR mutations andthe compensatory mechanism have largely limited their clinicalefficacy. Given the synergistic effect between EGFR and othercompensatory targets during tumorigenesis and tumor development,EGFR dual-target inhibitors are promising for their reduced risk ofdrug resistance, higher efficacy, lower dosage, and fewer adverseevents than those of single-target inhibitors. Hence, we present thesynergistic mechanism underlying the role of EGFR dual-targetinhibitors against drug resistance, their structure-activity relationships, and their therapeutic potential. Most importantly, weemphasize the optimal target combinations and design strategies for EGFR dual-target inhibitors and provide some perspectives on new challenges and future directions in this field.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available